



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 11, 2020

**BSE Ltd.**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code : 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: US FDA approval of New Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat**

We wish to inform you that the Company is in receipt of the Establishment Inspection Report (EIR) from the US FDA for the Company's newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat. The US FDA issues an EIR to the Company when an inspection is satisfactorily "closed". The said inspection was carried out from 24<sup>th</sup> June to 28<sup>th</sup> June 2019. At the end of the inspection, "No Objectionable Observation" were found and no Form 483 was issued.

This new facility known as (T20) has already been approved by the other regulatory authorities like EU, TGA-Australia, Saphra-South Africa. This is an another facility in addition to one already approved by US FDA.

The new facility will augment the Company's manufacturing capacity for regulated markets like USA, EU, Australia and South Africa.

We request you to take the above announcement on record.

Thanking you,

Yours faithfully,

**For J. B. Chemicals & Pharmaceuticals Limited**

**S.B. Mody**

**Whole time Director (Marketing)**